The KM plotter revealed that the survival rate of patients with a high expression of NEDD4 was shorter than that of patients with a low expression of NEDD4 in HER2-positive (HER2+) and TNBC, which have been known as relatively aggressive breast cancers (Figure 1A). This evidence concerns the gene ERBB2 and breast cancer.